1Richardson PG, Barlogie B, Berenson J, et al. Extendedfollow up of a phase trial in relapsed, refractory multi- ple myelomaFJ3. Cancer, 2006,106 : 1316-1319.
3Anderson KC, Alsina M,Bensinger W, et al. Multiple- myeloma, version 1. 2013 [J]. J Natl Compr Canc Netw, 2013,11: 11-17.
4Chanan-kena A, Miller KC. Velcade,Doxil and Thalid- omide (VDT) is an effective salvage regimen for pa- tients with relapsed and refractory multiple myeloma [J]. Leuk Lymphoma, 2005,46 : 1103-1104.
5Blade" J, Samson D, Reece D, et al. Criteria for evalua- ting disease response and progression in patients with multiple myeloma treated by high close therapy and haemopoietic stem cell transplantation. Myeloma Sub- committe for the EBMT[J]. Br J Haematol, 1998, 102:1115--1123.
6Adams J. The proteasome : structure, function, and role in the cell[J]. Cancer Treat Rev, 2O03,29: 3-9.
7Shan S, Potter M, Callery M. Ubiquitin proteasome pathway: implication and advances in cancer therapy [J]. Surg Oncol, 2001,10: 43- 52.
8Karin M, Cao Y, Greten F, et al. NF-kappaB in cancer : from innocent bystander to major culprit[J]. Nat Rev Cancer, 2002,2 : 301- 310.
9Bross PF,Kane R,Farrell AT,et al. Approval summa- ry for bortezomib for injection in the treatment of multiple myeloma [J]. Clin Cancer Res, 2004, 10.. 3954--3964.
2Barlogie B, Alexanian R, Smith L. Effective treatment of advanced multiple myeloma refractory to alkylating agents [ J]. N Eng J Med, 1984,310(21 ) : 1353 - 1356.
